




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Hypertriglyceridemia</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=f66067a7-924e-48e8-8362-69c077adf16b</link>
        <description>Clinical Topic Feed: Hypertriglyceridemia</description>
        <language>en</language>

        

                <item>
                    <title>CRHCP, SHASTA-3/4: Advances in Dementia and Triglyceride Management</title>
<link>/Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-1215pm-prevention-esc-2026</link>                    <description>The results from two Hot Line trials presented at ESC Congress 2026 hold promise for patients with high blood pressure (BP) at risk of dementia, and for patients with severe hypertriglyceridemia.</description>
                    <pubdate>1788106500000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC CardiaCast: Risk Assessment and Treatment of Hypertriglyceridemia</title>
<link>/Latest-in-Cardiology/Articles/2026/08/04/15/47/cardiacast_07aug2026</link>                    <description>This episode of CardiaCast will feature a discussion on risk assessment and the treatment of hypertriglyceridemia.</description>
                    <pubdate>1786111200000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC CardiaCast: Understanding the Spectrum: Causes and Risks of HTG and sHTG</title>
<link>/Latest-in-Cardiology/Articles/2026/06/26/15/21/cardiacast_26jun2026</link>                    <description>This episode is part of ACC&#226;€™s ongoing initiative to recognize the risks and tackle management of Hypertriglyceridemia (HTG) and Severe Hypertriglyceridemia (sHTG).</description>
                    <pubdate>1782752760000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Severe Hypertriglyceridemia: Acute Risk Stratification and Immediate Management</title>
<link>/Education-and-Meetings/Patient-Case-Quizzes/2026/06/09/16/23/Severe-Hypertriglyceridemia</link>                    <description>A 48-year-old man with a history of type 2 diabetes mellitus (T2DM), obesity (body mass index 34.0), and heavy alcohol use (approximately four to five drinks daily) presents to the clinic for a routine follow-up. He reports a 3-day history of mild diffuse abdominal discomfort but denies nausea, vomiting, or fever.</description>
                    <pubdate>1781025180000</pubdate>
                    <category>Educational Activities</category>
                </item>
                <item>
                    <title>Recurrent Extreme Hypertriglyceridemia: Diagnostic Workup and Suspecting Familial Chylomicronemia Syndrome</title>
<link>/Education-and-Meetings/Patient-Case-Quizzes/2026/06/09/16/23/Recurrent-Extreme-Hypertriglyceridemia</link>                    <description>A 29-year-old woman is referred to a lipid clinic following her second hospitalization because of acute pancreatitis in 18 months. She has no history of diabetes mellitus, alcohol use, hypothyroidism, or use of triglyceride (TG) level&#226;€“raising medications.</description>
                    <pubdate>1781025180000</pubdate>
                    <category>Educational Activities</category>
                </item>
                <item>
                    <title>Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume?</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/mon-830am-essence-acc-2026</link>                    <description>In patients with moderate hypertriglyceridemia, significant reductions in triglyceride and remnant cholesterol levels with olezarsen, on top of standard-of-care lipid-lowering therapy, did not translate into a significant change from baseline in noncalcified coronary plaque volume (NCPV), according to results from Essence-CTA, a substudy of the Essence-TIMI 73b trial, presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in Circulation.</description>
                    <pubdate>1774877580000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: New ACC/AHA Dyslipidemia Guidelines Released</title>
<link>/Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life.</description>
                    <pubdate>1773842400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/03/13/15/20/ACC-AHA-Release-New-Clinical-Guideline-For-Managing-Dyslipidemia</link>                    <description>The new ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive &#226;€œone-stop shop&#226;€ for addressing the evaluation, management and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]).</description>
                    <pubdate>1773415860000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Cover Story | The Adipokine Hypothesis: A New Framework For Understanding HFpEF</title>
<link>/Latest-in-Cardiology/Articles/2026/03/01/01/Cover-Story-The-Adipokine-Hypothesis</link>                    <description>Fourteen hours a day, nearly every day for a year. That&#39;s how long it took Milton Packer, MD, FACC, to write his groundbreaking hypothesis connecting adipokines and visceral adiposity to heart failure with preserved ejection fraction (HFpEF).</description>
                    <pubdate>1772371140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | PCI Symptom Relief in Older Adults; Smartwatch ECG Monitoring; More</title>
<link>/Latest-in-Cardiology/Articles/2026/03/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1772370600000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>